Pharmaceutical company Lupin Pharmaceuticals Inc revealed on Wednesday that it has signed an agreement with virtual doctor's appointment service PlushCare to allow treatment for bacterial vaginosis (BV) in adult women via PlushCare's virtual platform.
This will help meet patient needs during the COVID-19 pandemic, Lupin said.
BV is the most common vaginal infection in the US and is treated with a prescription antibiotic. If untreated, BV is associated with an increased risk of pelvic inflammatory disease, HIV, and other sexually transmitted infections.
PlushCare enables patients to easily book a virtual doctor's appointment, discuss symptoms, receive a prescription for lab testing and treatment, if necessary. The virtual health platform offers affordable medical services to patients in all 50 states.
Lupin Pharmaceuticals Inc is the US subsidiary of Indian pharmaceutical company Lupin Limited (NSE:LUPIN).
genedrive secures initial overseas orders for Genedrive MT-RNR1 ID kit
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results